58028-2

Tetrahydrogestrinone [Presence] in Urine

Active

Part Description

LP97963-0   Tetrahydrogestrinone
The identification of tetrahydrogestrinone (THG), the first true "designer androgen," as a sports doping agent reflects both an alarmingly sophisticated illicit manufacturing facility and an underground network of androgen abusers in elite sports, as well as the still untapped potential for designer androgens in medicine. Never marketed, THG was apparently developed as a potent androgen that was undetectable by conventional International Olympic Committee-mandated urinary sports doping tests. As a potent androgen and progestin with unspecified contaminants, its distribution for use at high doses without any prior biological or toxicological evaluation poses significant health risks. Yet this diversion of science also highlights the prospect of designer androgens for use in human medicine. Designer androgens also offer the possibility of tissue-specific effects enhancing the beneficial effects of androgens while mitigating the undesirable ones. Further developments require better understanding of the post receptor tissue selectivity of androgens, comparable to the mechanism underlying that of partial estrogen agonists (SERMs). This experience highlights the ongoing need for vigilance to detect novel drug doping strategies in order to maintain fairness and safety in elite sports. This will require the deployment of generic catch-all tests, such as sensitive and specific in vitro androgen bioassays, coupled with the development of mass spectrometry-based tests for specific doping agents. Starting from gestrinone, chemists can synthesize THG in one reaction step. PMID: 15934041, PMID: 15292520 Copyright Copyright ©2005-2009 Genome Alberta (Reference to original publication: Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009 37(Database issue):D603-610.) Source: Human Metabolome Database , Tetrahydrogestrinone

Fully-Specified Name

Component

Tetrahydrogestrinone

Property

PrThr

Time

Pt

System

Urine

Scale

Ord

Method

Additional Names

Long Common Name

Tetrahydrogestrinone [Presence] in Urine

Short Name

Tetrahydrogestrinone Ur Ql

Display Name

Tetrahydrogestrinone Ql (U)

Consumer Name Alpha Get Info

Tetrahydrogestrinone, Urine

Basic Attributes

Class

DRUG/TOX

Type

Laboratory

First Released

Version 2.29

Last Updated

Version 2.56 (MIN)

Change Reason

The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.

Order vs. Observation

Both

Language Variants Get Info

Related Names

• Addiction
• DRUG/TOXICOLOGY
• Drugs
• Drugs of abuse
• Illicit
• Ordinal
• Point in time
• PotentialForAbuse
• PR
• QL
• Qual
• Qualitative
• Random
• Screen
• UA
• UR
• Urn

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=58028-2

LOINC Copyright

Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.